antithrombotic effect

Betrixaban maleate is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa.

Etofylline clofibrate has a hypolipidemic and antithrombotic effect and it also has an agonistic interaction with intimal PGI2.

Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II). It also has an antithrombotic activity associated with a reduced risk of adverse bleeding events.

TA-993 is a calcium channel antagonist. TA-993 has an antithrombotic effect.

Darutigenol has obvious antithrombotic effect, its mechanism may be related to inhibition of platelet aggregation and adhesion.

Salvianolic acid B is a water-soluble antioxidant from Salvia extract. Salvianolic acid B plays significant role of antioxidant effect; antiplatelet aggregation, anticoagulant, and antithrombotic effect.

Bivalirudin TFA, a synthetic 20-residue peptide, serves as a reversible inhibitor of thrombin. Its IC50 value highlights its target specificity in vitro, where, combined with Eptifibatide (8 mg mL) at a low concentration (70 ng mL), it significantly reduces platelet aggregation induced by thrombin (0.2 U mL) by approximately 90% [1]. The compound demonstrates no effect on thrombin generation assay (TGA) parameters up to 10 μmol L [2]. Additionally, it facilitates the binding of MPO to BAEC, leading to functional alterations such as increased NO consumption and enhanced MPO-mediated redox modifications [3]. In vivo studies reveal its efficacy in preventing the rise of antiheparin PF4 antibody IgG levels in rats, with significant findings from the toxicokinetic assessment signaling its safety profile at tested doses, although higher doses resulted in fatalities [4][5]. In clinical trials, its antithrombotic effects were explored, comparing it with alternatives like Ticagrelor and Clopidogrel in a Phase 4 study.

MIPS-21335 is a potent PI3KC2α inhibitor with an IC50 value of 7 nM and additionally exhibits inhibitory activity against PI3KC2β, p110α, p110β, and p110δ with IC50 values of 0.043, 0.140, 0.386, and 0.742 μM, respectively. This compound demonstrates an antithrombotic effect [1].